Neurological Institute Outcomes
Headache
OnabotulinumtoxinA Therapy for Headache
Outcomes Following OnabotulinumtoxinA Treatment (N = 1477)
2022
HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System, GAD-7 = Generalized Anxiety Disorder Questionnaire
In 2021-2022, 1477 headache patients who were treated with onabotulinumtoxinA were reviewed. Following treatment, 92% had improved or stable headache impact,¹ PROMIS Global Health,² depression ,³ and anxiety scores.⁴